Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annu
MWN-AI** Summary
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company renowned for its innovative-induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, has announced that it will present preclinical data on its next-generation off-the-shelf CAR T-cell product candidate, FT839, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego from April 17-22, 2026. The company has been selected for a poster presentation showcasing the advances of FT839, which features a dual CAR system designed to target both CD19 and CD38, making it applicable for treating a range of hematological malignancies and autoimmune diseases.
One of the standout features of FT839 is the incorporation of Sword and Shield™ technology, which allows the CAR T-cells to evade and eliminate the host's allogeneic immune responses. Notably, this innovative approach eliminates the need for conditioning chemotherapy, which is often a requisite for conventional CAR T-cell therapies.
The poster presentation is scheduled for April 21, 2026, from 9:00 a.m. to noon PDT. As Fate Therapeutics continues to progress with their IND-enabling studies and applications for FT839, the implications of this research could redefine treatment paradigms within oncology and autoimmune disease therapy.
In the forward-looking statements section of their announcement, Fate Therapeutics highlighted potential risks associated with their product development, including the possibility that FT839 may not meet safety or efficacy benchmarks, challenges with clinical trial logistics, and the unpredictable nature of regulatory approvals. As with any clinical research, the road ahead involves numerous uncertainties, but the ongoing work with FT839 embodies a promising leap forward in the field of immunotherapy.
MWN-AI** Analysis
Fate Therapeutics (NASDAQ: FATE) recently announced the presentation of preclinical data for FT839, its innovative off-the-shelf CAR T-cell product candidate, at the AACR Annual Meeting in San Diego. FT839's unique attributes, including its 13-point editing and Sword and Shield™ technology, present a novel approach to treating hematological malignancies and autoimmune diseases, notably without the need for conditioning chemotherapy.
This significant advancement could potentially enhance FATE's competitive positioning in the rapidly evolving CAR T-cell space, particularly in light of the growing demand for more efficient and patient-friendly cancer therapies. The emphasis on eliminating the conditioning phase may increase patient accessibility, making FT839 appealing not just to oncologists but also to a broader patient demographic.
From an investment perspective, this novel approach could bolster investor confidence and attract attention from analysts closely monitoring CAR T developments. However, potential investors should remain cognizant of the inherent risks outlined in Fate's forward-looking statements, including regulatory hurdles and the uncertainty regarding clinical outcomes. Preclinical successes do not always translate to positive results in human trials, a reality that can significantly affect stock performance.
In light of these developments, short-term investors may want to monitor price movements surrounding the AACR presentation. Anticipation of positive data and strategic partnerships could drive the stock higher. However, given the speculative nature of biotechnology investments and the volatility associated with clinical-stage companies, long-term investors should perform thorough due diligence, assessing both the underlying science and market conditions.
In conclusion, while FT839's preclinical data presents an optimistic outlook for Fate Therapeutics, stakeholders should approach with cautioned optimism, balancing potential rewards against the risks inherent in biotechnology investing.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that preclinical data from the Company’s next-generation, off-the-shelf CAR T-cell product candidate, FT839, will be featured at the American Association for Cancer Research Annual Meeting, being held in San Diego, CA on April 17-22, 2026.
The Company has been selected to participate in a poster presentation featuring preclinical data from FT839, its next generation, 13-point edited, off-the-shelf CAR T-cell product candidate for the broad treatment of hematological malignancies and autoimmune diseases. In addition, FT839 incorporates Sword and Shield™ technology to evade and eliminate host allogeneic immune responses, promote functional persistence, and thereby eliminate the need for conditioning chemotherapy.
A link to the abstract can be found here: Fate AACR Abstract Poster presentation details are as follows:
Poster Presentation
Title: FT839: A next-generation, off-the-shelf CAR T-cell uniquely engineered with a dual CAR system targeting CD19 and CD38 for the treatment of hematological malignancies and autoimmune diseases without conditioning chemotherapy
Session: CAR T-Cell Functional Enhancement
Presentation Date / Time: Tuesday, April 21, 2026 / 9:00 a.m. to Noon PDT
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company’s product candidates, including FT839, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the Company’s plans to complete IND-enabling studies and to submit IND applications for its product candidates, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the therapeutic and market potential of the Company’s research and development programs and product candidates, and the Company’s clinical and product development strategy. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and risks relating to regulatory interactions and the outcome of such interactions. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Contact:
Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com
FAQ**
What are the anticipated clinical milestones for Fate Therapeutics Inc. (FATE) regarding the IND applications for their CAR T-cell candidate FT839 following its presentation at the AACR Annual Meeting?
How does Fate Therapeutics Inc. (FATE) plan to address the risks associated with the safety and efficacy of FT839 as they advance in clinical trials?
Can you elaborate on the Sword and Shield™ technology used by Fate Therapeutics Inc. (FATE) in FT839, particularly its impact on immune response and treatment outcomes?
What are the market implications for Fate Therapeutics Inc. (FATE) if FT839 demonstrates significant therapeutic benefits in treating hematological malignancies and autoimmune diseases?
**MWN-AI FAQ is based on asking OpenAI questions about Fate Therapeutics Inc. (NASDAQ: FATE).
NASDAQ: FATE
FATE Trading
8.92% G/L:
$2.005 Last:
2,280,086 Volume:
$2.02 Open:
